SCHEMBL2850065

SCHEMBL2850065

CCCCCN1CCCCC1O

nearest known ligand 0.47

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.47
S1PR3 Q99500 3/20 0.47
S1PR5 Q9H228 3/20 0.47
GBA1 P04062 4/20 0.46
S1PR4 O95977 1/20 0.45
GBA2 Q9HCG7 10/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10590808 0.98 S1PR1 (0.49) S1PR1S1PR3S1PR5GBA1S1PR4
SCHEMBL3428819 0.98 S1PR1 (0.49) S1PR1S1PR3S1PR5GBA1S1PR4
Methane SCHEMBL6600535 0.96 S1PR1 (0.48) S1PR1S1PR3S1PR5GBA1S1PR4
SCHEMBL3265496 0.94 S1PR1 (0.50) S1PR1S1PR3S1PR5GBA1S1PR4
SCHEMBL4229106 0.94 GBA2 (0.46) S1PR1S1PR3S1PR5GBA1S1PR4
Pyrrolidine SCHEMBL4393172 0.90 GBA1 (0.43) S1PR1S1PR3S1PR5GBA1S1PR4
SCHEMBL28123990 0.88 GBA2 (0.47) S1PR1S1PR3S1PR5GBA1S1PR4
SCHEMBL27675556 0.86 GBA1 (0.43) S1PR1S1PR3S1PR5GBA1GAA
SCHEMBL12513822 0.78 CXCR4 (0.51) S1PR1S1PR3S1PR5S1PR4
SCHEMBL25956532 0.78 CXCR4 (0.51) S1PR1S1PR3S1PR5S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10961216-B2 Small molecule modulators of the androgen receptor MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-03-30 US disclosed
US-20190202800-A1 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-07-04 US disclosed
WO-2019023651-A2 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-01-31 WO disclosed
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8710049-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-29 US disclosed
US-20130184262-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
WO-2013012827-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed
WO-2013012829-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed
EP-1893200-B1 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2010-09-29 EP disclosed
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2009-03-26 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed
EP-1893200-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-03-05 EP disclosed
WO-2006123244-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO disclosed
CN-1052144-A The Compounds and methods for of diagnosis and treatment cancer AUSTRALIAN COMMERCIAL RESEARCH (AU) 1991-06-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors GRM5, GRIK5, GRM1 S1PR1 1184/4885S1PR3 1079/4885S1PR5 451/4885
US-20130184262-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF NPY4R, NPY2R, NPY1R S1PR1 333/4885S1PR3 288/4885S1PR5 308/4885
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF NPY4R, NPY2R, NPY1R S1PR1 333/4885S1PR3 288/4885S1PR5 308/4885
US-20190202800-A1 SMALL MOLECULE MODULATORS OF THE ANDROGEN RECEPTOR AR, NR5A1, ESRRA S1PR1 2796/4885S1PR3 2128/4885S1PR5 1977/4885
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 S1PR1 1409/4885S1PR3 1014/4885S1PR5 891/4885
US-10961216-B2 Small molecule modulators of the androgen receptor AR, NR5A1, ESRRA S1PR1 2796/4885S1PR3 2128/4885S1PR5 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.